PremiumRatingsAlnylam Pharma’s Strong Q1 Performance and Strategic Initiatives Drive Buy Rating with $336 Price Target Alnylam Pharmaceuticals Reports Strong Q1 2025 Growth Alnylam Pharmaceuticals Reports Strong Start to 2025 PremiumRatingsAlnylam Pharma: Strong Financial Performance and Promising Growth Catalysts Justify Buy Rating Alnylam Pharma: Strong Buy Rating Driven by Robust RNAi Portfolio and Market Expansion Alnylam Pharma: Hold Rating Amid EU Approval Prospects and Pricing Challenges PremiumRatingsAlnylam Pharma: Strategic Positioning and Product Advancements Drive Buy Rating Alnylam price target raised to $328 from $325 at BofA Alnylam Pharma’s Promising Launch and Strategic Positioning Drive Buy Rating 
